Prevalence of ADHD: 2026 Report on Trends, Adult Persistence, and Diagnostic Criteria Effects

The prevalence of ADHD in 2026 is best understood not as a single number but as a time series shaped by three decades of shifting survey methods and diagnostic criteria. This report compiles year-by-year prevalence data from primary sources, with every figure labeled by data year, survey instrument, and the diagnostic criteria in effect at the time.

Compiled by researchers at New Frontiers, the #1 rated executive function coaching service in the U.S., the analysis traces how measured ADHD prevalence has risen across successive survey waves, why methodology drives much of that increase, and how childhood rates translate into adult persistence. You can find another current analysis of ADHD prevalence figures in How Common Is ADHD? 2026 Statistics.

ADHD Prevalence: 2026

Measured ADHD prevalence among U.S. children has climbed steadily since parent-report surveillance began in the late 1990s, when an estimated 7.0% of children aged 5–17 carried an ever-diagnosis in the 1997–1999 NHIS, to roughly 11.4% in the 2022 NSCH. That increase, however, unfolded alongside two major revisions to the DSM and repeated survey redesigns, so the trend line reflects a blend of true occurrence and evolving measurement. The lead series below tracks the primary parent-report estimates by data year, population, and the diagnostic criteria era in which each figure was collected.

ADHD Prevalence Trend Series by Data Year, Age Band, and Diagnostic Criteria Era

Sources: Table 1¹

National surveys are periodically redesigned; estimates from different versions of the same survey are not directly comparable. The 2016 NSCH used a new mail/online methodology and a broader 2–17 age range, which lowered its estimate relative to the 2011 telephone survey.

U.S. vs. Global ADHD Prevalence

U.S. measured prevalence sits well above pooled international figures. Still, much of that gap reflects methodology rather than true difference: U.S. surveillance counts parent-reported provider diagnoses, while many international estimates apply symptom-based research criteria to community samples. Pooled global estimates place childhood ADHD at roughly 7.2% and symptomatic adult ADHD at about 6.76%, both below the corresponding U.S. rates.

ADHD Prevalence: U.S. vs. Global by Population and Data Year

Sources: Table 2²

Childhood vs. Adult Persistence Rates

Persistence is the report’s most methodology-sensitive measure: estimates of how many children with ADHD still have it as adults range from 4% to 77% across studies, driven almost entirely by how “persistence” is defined. When only those meeting the full diagnostic criteria are counted, persistence at age 25 is roughly 15%; when partial-remission cases with residual impairment are included, the figure rises to about 65%. This definitional spread explains why adult prevalence (~6%) sits below childhood prevalence (~11%), as symptoms and diagnostic thresholds shift with age rather than disappearing outright.

ADHD Persistence from Childhood into Adulthood

Sources: Table 3³

How Diagnostic Criteria Changes Affected Measured Prevalence

When the DSM-5 was published in 2013, it broadened ADHD diagnosis in ways that directly raised measured prevalence. The age-of-onset threshold rose from 7 to 12 years, the adult symptom count required for diagnosis dropped from six to five, and pervasiveness was redefined around symptom presence rather than impairment across settings. Field data quantify the effect: in a nationally representative sample of U.S. 12- to 15-year-olds, applying the later age-of-onset threshold raised detection from 7.38% under DSM-IV to 10.84% under DSM-5, and separate modeling of young adults suggests a roughly 27% increase in expected prevalence from the criteria change alone.

DSM-IV vs. DSM-5 (2013) Criteria Changes and Measured Effect

Sources: Table 4⁴

Why Measured ADHD Prevalence Is Rising

The upward trend traces to at least three research-backed drivers rather than any single cause. First, broader diagnostic criteria (above) expanded the population that qualifies. Second, greater public awareness, reduced stigma, and expanded telehealth access fueled a sharp post-2020 surge in adult assessment and treatment. Third, survey redesigns and improved case ascertainment changed how prevalence is counted.

The clearest single-number illustration of the childhood trend is that approximately one million more U.S. children had ever received an ADHD diagnosis in 2022 (7.1 million) than in 2016 (6.1 million), according to CDC/NSCH data. On the adult side, the shift is best documented through treatment and diagnosis timing rather than a single population count: CDC analysis of commercial claims found that stimulant prescription fills rose from 3.6% of enrollees in 2016 to 4.1% in 2021. Crucially, the CDC itself cautions that it cannot be determined whether these rises reflect more actual ADHD or simply more diagnosis.

Drivers of Rising Measured ADHD Prevalence

Sources: Table 5⁵

Adult ADHD Diagnosis Trends Over Time

The adult trend is where 2026 data diverges most sharply from historical baselines. Adult current-diagnosis prevalence rose from the long-cited 4.4% (National Comorbidity Survey Replication, DSM-IV era) to 6.0% in the 2023 CDC Rapid Surveys, approximately 15.5 million adults, or about 1 in 16. Notably, more than half of diagnosed adults (55.9%) received their first diagnosis in adulthood rather than childhood, reflecting the post-2020 acceleration in adult recognition. The acceleration is corroborated by prescribing data: CDC found that the percentage of commercially insured enrollees with a stimulant fill rose steadily through 2016–2021, with the sharpest increases among adult women during the first two pandemic years.

Adult ADHD Prevalence and Diagnosis Trend by Data Year

Sources: Table 6⁶

Global ADHD Prevalence Trends, 1990–2021

Longitudinal international data add a final methodological layer. A Global Burden of Disease trend analysis covering 1990–2021 found the largest increases in incidence and prevalence in High and High-middle socio-demographic index (SDI) regions, with Australasia recording the highest 2021 rates and the UK, Spain, and China showing the steepest increases. At the same time, some pooled global measures trended flat or slightly downward across the full 30 years, a reminder that the direction of an ADHD trend often depends on which methodology and population frame are used.

Global ADHD Trend Highlights, 1990–2021 (GBD Analysis)

Sources: Table 7⁷

The Bottom Line

Read as a whole, the 2026 data indicate that measured ADHD prevalence is a function of true occurrence plus evolving criteria, awareness, and access, not occurrence alone. Childhood rates near 11% and adult rates near 6% represent the highest figures on record, and the adult trend in particular continues to climb. As diagnosis expands, so does the number of children and adults who may benefit from executive function support.

For related neurodevelopmental data, see Average Age of ADHD Diagnosis, Most Common Neurodivergent Conditions, and Dyslexia Statistics 2026. To learn how structured coaching supports academic and life outcomes for people with ADHD, explore New Frontiers ADHD coaching.

References

Table 1:

1. Trends in ADHD Among U.S. Children. (2026, July 8). CDC. https://www.cdc.gov/adhd/data/trends-in-adhd-US-children.html
2. Increasing Prevalence of Parent-Reported ADHD Among Children — United States, 2003 and 2007. (2010). MMWR. CDC. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5944a3.htm
3. Visser, S. N., et al. (2014). Trends in the Parent-Report of ADHD Diagnosis and Treatment, United States, 2003–2011. NSCH. https://pmc.ncbi.nlm.nih.gov/articles/PMC4473855/
4. Danielson, M. L., et al. (2018). Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016. https://pubmed.ncbi.nlm.nih.gov/29363986/
5. Danielson, M. L., Claussen, A. H., Bitsko, R. H., et al. (2024). ADHD Prevalence Among U.S. Children and Adolescents in 2022. Journal of Clinical Child & Adolescent Psychology, 53(3), 343–360. https://pubmed.ncbi.nlm.nih.gov/38778436/
6. Reuben, C., & Elgaddal, N. (2024, March). ADHD in Children Ages 5–17 Years: United States, 2020–2022. NCHS Data Brief No. 499. CDC. https://www.cdc.gov/nchs/products/databriefs/db499.htm
7. Staley, B. S., et al. (2024). ADHD Diagnosis, Treatment, and Telehealth Use in Adults — NCHS Rapid Surveys System, 2023. MMWR, 73(40), 890–895. https://doi.org/10.15585/mmwr.mm7340a1

Table 2:

1. Thomas, R., Sanders, S., Doust, J., Beller, E., & Glasziou, P. (2015). Prevalence of Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. Pediatrics, 135(4), e994–e1001. https://pubmed.ncbi.nlm.nih.gov/25733754/
2. Ayano, G., et al. (2023). The global prevalence of ADHD in children and adolescents: An umbrella review of meta-analyses. Journal of Affective Disorders. https://www.sciencedirect.com/science/article/pii/S0165032723009230
3. Danielson, M. L., et al. (2024). ADHD Prevalence Among U.S. Children and Adolescents in 2022. https://pubmed.ncbi.nlm.nih.gov/38778436/
4. Song, P., et al. (2021). The prevalence of adult ADHD: A global systematic review and meta-analysis. Journal of Global Health, 11, 04009. https://jogh.org/the-prevalence-of-adult-attention-deficit-hyperactivity-disorder-a-global-systematic-review-and-meta-analysis/

Table 3:

1. Faraone, S. V., Biederman, J., & Mick, E. (2006). The age-dependent decline of ADHD: A meta-analysis of follow-up studies. Psychological Medicine, 36(2), 159–165. https://scholars.mssm.edu/en/publications/the-age-dependent-decline-of-attention-deficit-hyperactivity-diso-2/
2. Biederman, J., Petty, C. R., Evans, M., Small, J., & Faraone, S. V. (2010), cited in Caye, A., et al. (2016). Predictors of persistence of ADHD into adulthood. European Child & Adolescent Psychiatry. https://link.springer.com/article/10.1007/s00787-016-0831-8
3. Klein, R. G., et al. (2012). 33-year follow-up of childhood ADHD, cited in Cambridge Core review. https://www.cambridge.org/core/journals/acta-neuropsychiatrica/article/14AA5ED9006BFE88205580076792CC51
4. Sibley, M. H., et al. (2016). Method of adult diagnosis influences estimated persistence of childhood ADHD. The Lancet Psychiatry. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(16)30190-0/abstract

Table 4:

1. American Psychiatric Association. (2013). DSM-5 Attention-Deficit/Hyperactivity Disorder Fact Sheet. https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM-5-ADHD.pdf
2. Vande Voort, J. L., He, J.-P., Jameson, N. D., & Merikangas, K. R. (2014). Impact of the DSM-5 Attention-Deficit/Hyperactivity Disorder Age-of-Onset Criterion in the US Adolescent Population. Journal of the American Academy of Child & Adolescent Psychiatry, 53(7), 736–744. https://www.sciencedirect.com/science/article/abs/pii/S089085671400255X
3. Matte, B., et al. (2015). ADHD in DSM-5: a field trial in a large, representative sample of 18- to 19-year-old adults. Psychological Medicine, 45(2), 361–373. https://pmc.ncbi.nlm.nih.gov/articles/PMC4301194/
4. Adult ADHD Diagnosis, Management, and Treatment in the DSM-5 Era. (2024). The Primary Care Companion for CNS Disorders. https://www.psychiatrist.com/pcc/adult-adhd-in-the-dsm-era/

Table 5:

1. Trends in ADHD Among U.S. Children. (2026). CDC. https://www.cdc.gov/adhd/data/trends-in-adhd-US-children.html
2. Facts About ADHD Throughout the Years. (2024, October 23). CDC. https://www.cdc.gov/adhd/data/adhd-throughout-the-years.html
3. Danielson, M. L., Bohm, M. K., Newsome, K., et al. (2023). Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults — United States, 2016–2021. MMWR, 72(13), 327–332. https://www.cdc.gov/mmwr/volumes/72/wr/mm7213a1.htm
4. Danielson, M. L., Claussen, A. H., Bitsko, R. H., et al. (2024). ADHD Prevalence Among U.S. Children and Adolescents in 2022. https://pubmed.ncbi.nlm.nih.gov/38778436/

Table 6:

1. Kessler, R. C., et al. National Comorbidity Survey Replication (NCS-R), cited in Adult ADHD in the DSM-5 Era. https://www.psychiatrist.com/pcc/adult-adhd-in-the-dsm-era/
2. Danielson, M. L., Bohm, M. K., Newsome, K., et al. (2023). Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults — United States, 2016–2021. MMWR, 72(13), 327–332. https://www.cdc.gov/mmwr/volumes/72/wr/mm7213a1.htm
3. Staley, B. S., et al. (2024). ADHD Diagnosis, Treatment, and Telehealth Use in Adults — NCHS Rapid Surveys System, 2023. MMWR, 73(40), 890–895. https://doi.org/10.15585/mmwr.mm7340a1
4. Ashman, J. J., et al. (2025, December 18). Visits to Health Centers by Adults With ADHD: United States, 2023. NCHS Data Brief No. 543. CDC. https://www.cdc.gov/nchs/data/databriefs/db543.pdf

Table 7:

1. Global, regional, and national burdens of attention deficit hyperactivity disorder in adolescents and young adults aged 10–24 years from 1990 to 2021: A trend analysis. (2025). Frontiers in Psychiatry / PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928412/